FBXO33

Across TCGA pan-cancer cohorts, FBXO33 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FBXO33 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FBXO33 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FBXO33 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD and LSCC are the cancer types where FBXO33 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.603	0.933	.005	16	view →
LSCC	OS	Tertile	II,III,IV	0.897	0.529	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FBXO33–LUAD (OS)

Open the LUAD breakdown →